

REMARKS

The amendments to the Sequence Listing merely add the information appearing in Figures 5 and 6, aided by the definitions of abbreviations at pages 125 to 128. The amendments to the specification merely add appropriate cross-references to the Sequence Listing. All of such information added to the Sequence Listing is supported in the specification as filed and no new matter is added by this amendment.

Respectfully submitted,



Timothy J. Gaul

Attorney for Applicant

Registration No.: 33,111

Phone: (805) 447-2688

Date: August 13, 2002

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

D



VERSION WITH MARKINGS TO SHOW CHANGES MADE

Figure 5 shows a synthetic scheme for the preparation of PEGylated peptide 19 (SEQ ID NO: 3) as prepared through intermediates having SEQ ID NOS: 1128 through 1131, respectively.

Figure 6 shows a synthetic scheme for the preparation of PEGylated peptide 20 (SEQ ID NO: 4) as prepared through intermediates having SEQ ID NOS: 1132 and 1133, respectively.

RECEIVED  
AUG 19 2002  
TECH CENTER 1600/2900

D